Pelacarsen sodium clinical trials
Also written ISIS 681257.
A product of Pelacarsen; its studies count on that page too.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses pelacarsen sodium has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ISIS 681257
- 4
Studies by the year they started
4 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2017 | 3 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Pelacarsen
Studies
Open first, then newest update. How each study uses pelacarsen sodium has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular DiseaseCompletedPhase 2Akcea TherapeuticsNCT03070782Written as ISIS 681257How we knowReport a problem
- Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy PatientsCompletedPhase 1Akcea TherapeuticsNCT03506854Written as ISIS 681257How we knowReport a problem
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on WarfarinCompletedPhase 1Akcea TherapeuticsNCT03426033Written as ISIS 681257How we knowReport a problem
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on ClopidogrelCompletedPhase 1Akcea TherapeuticsNCT03392051Written as ISIS 681257How we knowReport a problem
Tested on its own · 2 — no other medicine in its arm
- Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular DiseaseCompletedPhase 2Akcea TherapeuticsNCT03070782Written as ISIS 681257How we knowReport a problem
- Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy PatientsCompletedPhase 1Akcea TherapeuticsNCT03506854Written as ISIS 681257How we knowReport a problem
Tested in a combination · 2 — another drug in the study is under test too
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on WarfarinCompletedPhase 1Akcea TherapeuticsNCT03426033Written as ISIS 681257How we knowReport a problem
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on ClopidogrelCompletedPhase 1Akcea TherapeuticsNCT03392051Written as ISIS 681257How we knowReport a problem
Codes
What other systems call pelacarsen sodium · ClinicalTrials.gg INT016264
- UNII (FDA) D1J27662O8PELACARSEN SODIUMOne source FDA
- NCI Thesaurus C174665Pelacarsen SodiumOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | D1J27662O8 | PELACARSEN SODIUM | One source FDA |
| NCI Thesaurus | C174665 | Pelacarsen Sodium | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.